19 completed, 9 terminated, 5 recruiting, 4 active not recruiting. 42 Phase 2, 15 Phase 1.
Follow entinostat: new trials by email Literature Review of entinostat trials Research Report on entinostat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Single-arm, Prospective, Phase II Clinical Study of the Combination of Entinostat and Oral Paclitaxel in the Treatment of HR+HER2- Advanced Breast Cancer Entinostat, Oral Paclitaxel - Breast Cancer | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 50 | 2026-04-01 | 2026-03-02 |
| A Study of Entinostat in Combination With Fulvestrant for the Treatment of Locally Advanced or Metastatic Breast Cancer Entinostat, Fulvestrant - Locally Advanced or Metastatic Breast Cancer | Phase 2 | Not yet recruiting | Sun Yat-sen University | 50 | 2026-01-05 | 2025-11-19 |
| Entinostat & Chemotherapy for Locally Advanced or Metastatic Bladder Cancer Entinostat, Chemotherapy - Bladder Cancer, Histone Deacetylase Inhibitor | Phase 1 / Phase 2 | Not yet recruiting | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 29 | 2025-12-01 | 2025-12-03 |
| A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy entinostat, Fulvestrant, Anlotinib - Breast Cancer | Phase 2 | Recruiting | Zhejiang Cancer Hospital | 118 | 2025-11-24 | 2026-01-09 |
| Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer entinostat, Dalpiciclib, Letrozole - Breast Cancer | Phase 2 | Recruiting | Hebei Medical University Fourth Hospital | 60 | 2025-09-12 | 2026-04-02 |
| Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure entinostat, Pyrotinib, endocrine therapy - Breast Cancer, HER2-positive Breast Cancer | Phase 1 / Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 94 | 2025-06-23 | 2026-07-16 |
| Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer Nivolumab, Entinostat, Montanide(R) ISA-51 VG Adjuvant - Neoplasms, Esophageal Neoplasms | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2024-08-02 | 2024-08-05 | |
| Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors BET Bromodomain Inhibitor ZEN-3694, Computed Tomography, Core Biopsy - Advanced Malignant Solid Neoplasm, Locally Advanced Pancreatic Carcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 49 | 2022-11-16 | 2026-07-15 |
| A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers Bintrafusp Alfa, PDS01ADC, Entinostat - Oropharyngeal Cancer, Neck Cancer | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 55 | 2021-10-05 | 2026-09-22 |
| Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer Pembrolizumab, Entinostat, Procedure/Surgery - Bladder Cancer | Phase 2 | Active not recruiting | UNC Lineberger Comprehensive Cancer Center | 20 | 2020-09-23 | 2026-10-23 |
| INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies Nivolumab and Entinostat - CNS Tumor, Solid Tumor | Phase 1 / Phase 2 | Recruiting | University Hospital Heidelberg | 91 | 2020-05-26 | 2024-02-07 |
| An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma Entinostat, Pembrolizumab - Melanoma | Phase 2 | Completed | UNC Lineberger Comprehensive Cancer Center | 11 | 2019-03-22 | 2024-01-10 |
| Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma Entinostat, Nivolumab, Ipilimumab - Renal Cell Carcinoma | Phase 2 | Terminated | Roberto Pili | 12 | 2018-07-31 | 2024-09-03 |
| High Dose IL 2 and Entinostat in RCC Entinostat, Interleukin-2 - Renal Cell Carcinoma | Phase 2 | Active not recruiting | Roberto Pili | 46 | 2018-05-24 | 2023-09-01 |
| Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the Eye Pembrolizumab, Entinostat - Metastatic Uveal Melanoma | Phase 2 | Completed | Vastra Gotaland Region | 29 | 2018-02-21 | 2023-12-08 |
| A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody, Bevacizumab, Entinostat - Breast Neoplasms | Phase 1 / Phase 2 | Completed | Hoffmann-La Roche | 144 | 2017-12-22 | 2025-11-10 |
| Entinostat Neuroendocrine (NE) Tumor Entinostat - Neuroendocrine Tumors | Phase 2 | Terminated | Antonio Fojo | 5 | 2017-12-13 | 2026-03-02 |
| A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma Entinostat, Nivolumab - Metastatic Cholangiocarcinoma, Cholangiocarcinoma | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 44 | 2017-11-06 | 2025-05-28 |
| Phase 2 Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer Entinostat, Entinostat(Placebo), Exemestane - Advanced or Recurrent Breast Cancer | Phase 2 | Completed | Kyowa Kirin Co., Ltd. | 133 | 2017-09-22 | 2022-06-21 |
| Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma Atezolizumab, Bevacizumab, Entinostat - Metastatic Cancer, Renal Cancer | Phase 1 / Phase 2 | Terminated | Roberto Pili | 31 | 2017-06-29 | 2025-03-20 |
Showing 20 of 42. Sign in to see all of them.
Breast Neoplasms (13) · Carcinoma, Non-Small-Cell Lung (7) · Carcinoma, Renal Cell (3) · Melanoma (3) · Colonic Neoplasms (2) · Leukemia, Myeloid, Acute (2) · Leukemia, Myelomonocytic, Acute (2) · Leukemia, Myelomonocytic, Chronic (2) · Lung Neoplasms (2) · Neoplasm Metastasis (2) · Pancreatic Neoplasms (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Recurrence (2) · Triple Negative Breast Neoplasms (2) · Urinary Bladder Neoplasms (2)
National Cancer Institute (NCI) (12) · Syndax Pharmaceuticals (9) · Roberto Pili (3) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · Tianjin Medical University Cancer Institute and Hospital (2) · UNC Lineberger Comprehensive Cancer Center (2) · Antonio Fojo (1) · Bayer (1) · Hebei Medical University Fourth Hospital (1) · Hoffmann-La Roche (1) · Kyowa Kirin Co., Ltd. (1) · Memorial Sloan Kettering Cancer Center (1) · Sun Yat-sen University (1) · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (1) · University Hospital Heidelberg (1)
United States (31) · China (5) · Sweden (2) · Australia (1) · Austria (1) · Canada (1) · Czechia (1) · France (1) · Georgia (1) · Germany (1) · Hungary (1) · Ireland (1) · Israel (1) · Japan (1) · Netherlands (1)
Denise Yardley, MD (2) · Roberto Pili, MD (2) · Alex Adjei, MD (1) · Alison Moskowitz, MD (1) · Antonio Fojo, MD, PhD (1) · B. Smith (1) · Charles Rudin (1) · David S Schrump, M.D. (1) · Dennis Slamon, MD (1) · Hongqian Guo, PhD (1) · Hoyoung M Maeng, M.D. (1) · John Wrangle (1) · Julie Brahmer (1)
PMID 24583822, PMID 22586682, PMID 23650416, PMID 26577691, PMID 27151994, PMID 31046743, PMID 32503469, PMID 33203644, PMID 34453044, PMID 36398439, PMID 37377898, PMID 38886159, PMID 39532835, PMID 39863139
U01CA070095 (5), P30CA006973 (4), N01CM00038 (2), N01CM00099 (2), UM1CA186691 (2), 2004 (1), 2009 (1), 2017 (1), 2018 (1), N01CM62205 (1), P01CA247886 (1), P30CA015083 (1), P30CA016056 (1), R21CA137649 (1), U01CA062505 (1)